

NEWSLETTER

Phase Holographic Imaging PHI AB (publ)

Lund, March 2, 2020

New CEO commentary: “Joining forces with Huntsman”



PHI recently joined forces with the Huntsman Cancer Institute in the battle against cancer. Using PHI's HoloMonitor technology, the researchers at Huntsman aim to develop improved methods for quantifying the phenomena that regulate tumors' ability to metastasize.

Read the commentary [here](#).

About PHI

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

For additional information, please contact:

Peter Egelberg, CEO

Tel: +46 703 19 42 74

E-mail: ir@phiab.se

Web: www.phiab.com